PDRX OTC
PD-Rx Pharmaceuticals, Inc.
1W: +0.0%
1M: +0.0%
3M: -7.5%
YTD: +6.9%
1Y: +8.8%
3Y: -48.3%
5Y: +8.8%
$3.10
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$19M
-10.9% ▼
5Y CAGR: -1.9%
Gross Profit
$6M
-16.2% ▼
5Y CAGR: -5.8%
Operating Income
-$952K
-399.8% ▼
Net Income
-$753K
-668.4% ▼
EPS (Diluted)
$-0.46
-666.7% ▼
EBITDA
-$560K
-4660.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $21M | $22M | $29M | $21M | $19M |
| YoY Growth | +0.7% | +2.7% | +32.9% | -25.9% | -10.9% |
| Cost of Revenue | $15M | $15M | $18M | $15M | $13M |
| Gross Profit | $6M | $7M | $11M | $7M | $6M |
| Gross Margin | 29.8% | 32.2% | 38.5% | 31.6% | 29.7% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $6M | $6M | $7M | $7M | $7M |
| Operating Expenses | $6M | $6M | $7M | $7M | $7M |
| Operating Income | -$238K | $876K | $4M | -$190K | -$952K |
| Operating Margin | -1.1% | 4.1% | 13.9% | -0.9% | -5.0% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$201K | $2M | $4M | -$127K | -$712K |
| Tax Expense | $184K | -$22K | $1M | -$29K | $41K |
| Net Income | -$384K | $2M | $3M | -$98K | -$753K |
| Net Margin | -1.8% | 8.6% | 10.6% | -0.5% | -4.0% |
| EPS (Diluted) | $-0.22 | $1.08 | $1.83 | $-0.06 | $-0.46 |
| EBITDA | -$40K | $2M | $4M | $12K | -$560K |
| Shares Outstanding | 2M | 2M | 2M | 2M | 2M |